Table 1. Baseline characteristics of spontaneous regression within the study sample.

Patient characteristics*	Oral (n=46)	Esophageal (n=11)	Gastric (n=38)	Peritoneal (n=3)	Hepatobiliary (n=212)	Pancreatic (n=10)	Small bowel (n=10)	Colorectal  (n=60)	Total (n=390)
Age (Mean (SD))	61.2 (17.4)	59.0 (16.2)	60.1 (19.0)	47.7 (15.9)	64.7 (13.5)	50.4 (18.2)	51 (16.2)	62.1 (15.0)	63.1 (14.7)
Age group (n (%))
<19	1 (2.2%)	0	1 (2.6%)	0	0	0	0	1 (1.7%)	3 (0.8%)
19-34	3 (6.5%)	1 (9.1%)	2 (5.3%)	0	6 (2.8%)	2 (20.0%)	1 (10.0%)	1 (1.7%)	16 (4.1%)
35-44	1 (2.2%)	1 (9.1%)	7 (18.4%)	2 (66.7%)	6 (2.8%)	1 (10.0%)	2 (20.0%)	7 (11.7%)	27 (6.9%)
45-54	11 (23.9%)	1 (9.1%)	2 (5.3%)	0	21 (9.9%)	1 (10.0%)	1 (10.0%)	7 (11.7%)	44 (11.3%)
55-64	8 (17.4%)	4 (36.4%)	10 (26.3%)	0	49 (23.1%)	2 (20.0%)	5 (50.0%)	17 (28.3%)	95 (24.4%)
65-74	9 (19.6%)	2 (18.2%)	5 (13.2%)	1 (33.3%)	82 (38.7%)	1 (10.0%)	1 (10.0%)	13 (21.7%)	114 (29.2%)
75-84	11 (23.9%)	2 (18.2%)	10 (26.3%)	0	43 (20.3%	1 (10.0%)	0	12 (20.0%)	79 (20.3%)
85+	2 (4.3%)	0	1 (2.6%)	0	4 (1.9%)	0	0	2 (3.3%)	9 (2.3%)
Sex (n (%))
Male	25 (54.3%)	8 (72.7%)	23 (60.5%)	2 (66.7%)	168 (79.2%)	6 (60.0%)	5 (50.0%)	35 (58.3%)	272 (69.7%)
Female	21 (45.7%)	3 (27.3%)	15 (39.5%)	1 (33.3%)	44 (20.8%)	4 (40.0%)	5 (50.0%)	25 (41.7%)	118 (30.3%)
Site of Regression (n (%))
Primary tumor/Recurrence	41 (89.1%)	8 (72.7%)	35 (92.1%)	0	194 (91.5%)	10 (100.0%)	7 (70.0%)	48 (80.0%)	288 (73.8%)
Lung metastases	2 (4.3%)	3 (27.3%)	0	1 (33.3%)	28 (13.2%)	0	1 (10.0%)	2 (3.3%)	37 (9.5%)
Liver metastases	0	0	1 (2.6%)	1 (33.3%)	2 (0.9%)	2 (20.0%)	2 (20.0%)	10 (16.7%)	18 (4.6%)
Lymph metastases	5 (10.9%)	2 (18.2%)	1 (2.6%)	0	2 (0.9%)	0	3 (30.0%)	2 (3.3%)	15 (3.8%)
Other metastases	1 (2.2%)	1 (9.1%)	1 (2.6%)	1 (33.3%)	13 (6.1%)	0	1 (10.0%)	6 (10.0%)	24 (6.2%)
Extent of regression (n (%))
Complete	43 (93.5%)	9 (81.8%)	32 (84.2%)	2 (66.7%)	156 (73.6%)	8 (80.0%)	10 (100.0%)	57 (95.0%)	317 (81.3%)
Partial	3 (6.5%)	2 (18.2%)	6 (15.8%)	1 (33.3%)	56 (26.4%)	2 (20.0%)	0	3 (5.0%)	73 (18.7%)
Histological profile (n (%))
Carcinoma	11 (23.9%)	8 (72.7%)	8 (21.1%)	0	198 (93.4%)	9 (90.0%)	1 (10.0%)	54 (90.0%)	289 (74.1%)
Primary lymphoma	28 (60.9%)	1 (9.1%)	24 (63.2%)	0	4 (1.9%)	0	6 (60.0%)	4 (6.7%)	67 (17.2%)
NET	1 (2.2%)	0	6 (15.8%)	0	2 (0.9%)	1 (10.0%)	1 (10.0%)	1 (1.7%)	12 (3.1%)
Other	6 (13.0%)	2 (18.2%)	0	3 (100.0%)	8 (3.8%)	0	2 (20.0%)	1 (1.7%)	22 (5.6%)
Period of regression (n (%))
<1 month	4 (8.7%)	0	3 (7.9%)	0	6 (2.8%)	0	0	0	13 (3.3%)
1-1.5 months	3 (6.5%)	1 (9.1%)	5 (13.2%)	0	11 (5.2%)	1 (10.0%)	0	9 (15.0%)	30 (7.7%)
2-5 months	2 (4.3%)	2 (18.2%)	6 (15.8%)	1 (33.3%)	27 (12.7%)	0	3 (30.0%)	13 (21.7%)	54 (13.8%)
6-11 months	6 (13.0%)	3 (27.3%)	3 (7.9%)	0	16 (7.5%)	1 (10.0%)	3 (30.0%)	1 (1.7%)	33 (8.5%)
12-23 months	6 (13.0%)	2 (18.2%)	5 (13.2%)	0	41 (19.3%)	2 (20.0%)	0	9 (15.0%)	65 (16.7%)
24-35 months	6 (13.0%)	1 (9.1%)	4 (10.5%)	1 (33.3%)	30 (14.2%)	1 (10.0%)	0	3 (5.0%)	46 (11.8%)
36-47 months	5 (10.9%)	0	2 (5.3%)	0	14 (6.6%)	1 (10.0%)	1 (10.0%)	5 (8.3%)	28 (7.2%)
48 months+	8 (17.4%)	1 (9.1%)	8 (21.1%)	1 (33.3%)	33 (15.6%)	4 (40.0%)	2 (20.0%)	17 (28.3%)	74 (19.0%)
Unspecified	6 (13.0%)	1 (9.1%)	2 (5.3%)	0	34 (16.0%)	0	1 (10.0%)	3 (5.0%)	47 (12.1%)
Malignancy recurrence (n (%))
Reported	5 (10.9%)	0	1 (2.6%)	0	14 (6.6%)	1 (10.0%)	2 (20.0%)	1 (1.7%)	24 (6.2%)
Not reported	41 (89.1%)	11 (100.0%)	37 (97.4%)	3 (100.0%)	198 (93.4%)	9 (90.0%)	8 (80.0%)	59 (98.3%)	366 (93.8%)